Skip to main content
Premium Trial:

Request an Annual Quote

CeMines Estonian Subsidiary Receives CE Mark for Lung Cancer Dx

NEW YORK, Jan. 12 (GenomeWeb News) - The European Union's regulatory body cleared the CellCorrect Lab Detection Kit for clinical use, CeMines said today.

 

EU's State Agency of Medicines-Department of Medical Devices on Dec. 30, 2005, granted the CE Mark for the molecular blood test to detect and diagnose lung cancer. CeMines Estonia OU, a wholly owned subsidiary, filed for CE Mark registration in September 2005.  

 

CeMines Estonia will market and distribute the test under the brand name CellCorrect KvA-40 LAb Kit.

 

CeMines filed a 501(k) application for CellCorrect Lab with the US Food and Drug Administration in May 2005. Claiming "productive discussions" with the FDA, the company expects "substantial forward progress" in 2006.

The Scan

Team Tracks Down Potential Blood Plasma Markers Linked to Heart Failure in Atrial Fibrillation Patients

Researchers in BMC Genomics found 10 differentially expressed proteins or metabolites that marked atrial fibrillation with heart failure cases.

Study Points to Synonymous Mutation Effects on E. Coli Enzyme Activity

Researchers in Nature Chemistry saw signs of enzyme activity shifts in the presence of synonymous mutations in a multiscale modeling analysis of three Escherichia coli genes.

Team Outlines Paternal Sample-Free Single-Gene Approach for Non-Invasive Prenatal Screening

With data for nearly 9,200 pregnant individuals, researchers in Genetics in Medicine demonstrate the feasibility of their carrier screening and reflex single-gene non-invasive prenatal screening approach.

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.